DENVER – Key members of BioScrip’s leadership team will continue in executive roles with the combined company following the close of its pending merger with Option Care Enterprises.
DENVER – BioScrip reported revenues of $179 million for the first quarter of 2019, an increase of 6.2% over the first quarter of 2018. Net loss from continuing operations was $10.3 million vs. $13 million.
When the ink dries on the planned merger of two of the country’s leading home infusion services providers, it will form an organization that is deeply committed to patient care, says John Rademacher, CEO of the combined company of Option Care and BioScri
DENVER, Colo., and BANNOCKBURN, Ill. – Option Care CEO John Rademacher says its merger with BioScrip will create a “powerful, independent platform” in the growing $100 million infusion market.
PHOENIX – Patients with short bowel system receiving parenteral nutrition can avoid hospital readmissions when clinical interventions are provided by a nutrition support team, according to a new study from Option Care.
DENVER – BioScrip and Option Care Enterprises, two of the largest independent providers of home infusion therapy services, have entered into a definitive merger agreement, the companies announced on March 15.
DENVER – BioScrip and Option Care Enterprises, two of the largest independent providers of home infusion therapy services, have entered into a definitive merger agreement, the companies announced on March 15.
INDIANAPOLIS – Rehab Medical has acquired OMS Rehab, a Kansas City, Mo.-based provider of orthotic devices and advanced rehabilitation equipment to long-term care facilities.
Bannockburn, Ill.-based Option Care has been chosen by Paratek Pharmaceuticals as a limited network provider of its new IV and oral antibiotic Nuzyra, to treat adults with community-acquired pneumonia and acute bacterial skin infections.
